Results 61 to 70 of about 9,288,830 (350)

Pre- and post-EndoPredict endocrine therapy regimens.

open access: yes, 2020
Pre- and post-EndoPredict endocrine therapy regimens.
Veronica Bautista-Piña (177269)   +11 more
core   +1 more source

Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer [PDF]

open access: yes, 2017
Objective: Although clinical trials recommend that women with hormone-dependent primary breast cancer remain on endocrine therapy for at least 5 years, up to 60% discontinue treatment early. We determined whether these women had consulted with clinicians
David Preen   +13 more
core   +1 more source

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment [PDF]

open access: yes, 2021
Endocrine therapy (ET) has established itself as an efficacious treatment for estrogen receptor-positive (ER+) breast cancers, with a reduction in recurrence rates and increased survival rates. The pre-surgical approach with chemotherapy (NCT) has become
Covadonga Martí   +4 more
core   +1 more source

Association between Endocrine Therapy and Weight Gain after Breast Cancer Diagnosis among Japanese Patients: A Retrospective Cohort Study

open access: yesMedical Sciences, 2021
Background: This study aimed to investigate the association between endocrine therapy and weight gain with a history of breast cancer. Methods: This was a retrospective cohort study.
Koki Okumatsu   +4 more
doaj   +1 more source

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

open access: yesNew England Journal of Medicine
BACKGROUND Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of ...
A. Bardia   +19 more
semanticscholar   +1 more source

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

open access: yesJAMA Oncology, 2019
Key Points Question Does treatment with abemaciclib plus fulvestrant prolong the overall survival (OS) of patients with hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer who progressed during prior endocrine therapy ...
G. Sledge   +18 more
semanticscholar   +1 more source

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer

open access: yes, 2023
The largest part of human DNA is transcribed into RNA that does not code for proteins. These non-coding RNAs (ncRNAs) are key regulators of protein-coding gene expression and have been shown to play important roles in health, disease and therapy response.
Ortmann, Olaf   +5 more
core   +1 more source

Association of serum 25-hydroxyvitamin D with the risk of depression in individuals with prediabetes and diabetes: A prospective cohort study

open access: yesThe Journal of Nutrition, Health and Aging
Objective: Serum 25-hydroxyvitamin D [25(OH)D] is known to be associated with depression. However, the evidence concerning the association between vitamin D status and depressive episodes in population with prediabetes and diabetes remains limited.
Huaxue Li   +11 more
doaj   +1 more source

Notch Signaling Pathway and Endocrine Resistance in Breast Cancer

open access: yesFrontiers in Pharmacology, 2020
Nearly 70% of breast cancers express the estrogen receptor (ER) and are hormone-dependent for cell proliferation and survival. Anti-estrogen therapies with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) or selective estrogen ...
Jing-Wen Bai   +6 more
doaj   +1 more source

Sleep and endocrine therapy in breast cancer

open access: yesCurrent Opinion in Endocrine and Metabolic Research, 2021
Sleep disturbances and insomnia are common among breast cancer survivors, and can have a significant effect on quality of life and numerous other significant outcomes.
K. V. Van Dyk, H. Joffe, J. Carroll
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy